Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. [electronic resource]
Producer: 20170728Description: 1154-1161 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Busulfan -- administration & dosage
- Cause of Death
- Cyclosporine -- administration & dosage
- Disease-Free Survival
- Female
- Graft vs Host Disease -- etiology
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Immunosuppressive Agents -- therapeutic use
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute -- therapy
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Myelodysplastic Syndromes -- therapy
- Recurrence
- Survival Rate
- Transplantation Conditioning -- adverse effects
- Transplantation, Homologous
- Vidarabine -- administration & dosage
- Whole-Body Irradiation
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.